Financial Performance - The company's operating revenue for Q1 2022 reached ¥93,489,632.76, representing a year-on-year increase of 39.21% due to increased sales of medical endoscope instruments[5] - Net profit attributable to shareholders was ¥35,792,018.79, up 36.98% year-on-year, while the net profit after deducting non-recurring gains and losses increased by 34.19%[5] - Total revenue for Q1 2022 reached ¥93,489,632.76, a 39.2% increase from ¥67,158,223.15 in Q1 2021[20] - Net profit attributable to shareholders for Q1 2022 was ¥35,792,018.79, up from ¥26,130,147.11 in Q1 2021, representing a 37.9% growth[21] - Operating profit for Q1 2022 was ¥41,243,659.55, compared to ¥29,498,981.37 in Q1 2021, indicating a 39.9% increase[20] Cash Flow and Assets - The net cash flow from operating activities decreased by 25.21% year-on-year, primarily due to a government subsidy of ¥12.73 million received in Q1 2021; excluding this, the cash flow would have increased by 24.81%[7] - Cash flow from operating activities in Q1 2022 was ¥23,469,085.19, down from ¥31,378,337.96 in Q1 2021[22] - The company's cash and cash equivalents as of March 31, 2022, amount to ¥317,399,284.25, a decrease from ¥723,080,364.17 on December 31, 2021[18] - Cash and cash equivalents at the end of Q1 2022 were ¥317,365,068.90, down from ¥795,720,865.79 at the end of Q1 2021[23] - The company reported a net cash outflow from investing activities of ¥427,691,546.92 in Q1 2022, compared to an outflow of ¥15,256,825.03 in Q1 2021[23] Research and Development - Research and development expenses totaled ¥10,630,408.34, marking a 45.17% increase compared to the same period last year, driven by an increase in R&D personnel and project investments[7] - Research and development expenses for Q1 2022 totaled ¥10,630,408.34, up from ¥7,322,569.49 in Q1 2021, reflecting a 45.5% increase[20] - The proportion of R&D investment to operating revenue increased by 0.47 percentage points to 11.37%[6] - Research and development expenses for Q1 2022 were CNY 4,262,572.05, an increase of 11.5% from CNY 3,824,385.44 in Q1 2021[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 2,859[14] - The largest shareholder, Qingdao Poda Enterprise Management, holds 10,920,000 shares, representing 12.55% of total shares[14] - The second largest shareholder, Zheng Anmin, holds 10,500,000 shares, accounting for 12.07%[14] Financial Position - The total assets at the end of the reporting period were ¥1,209,559,169.78, reflecting a 2.35% increase from the end of the previous year[6] - Total assets as of Q1 2022 amounted to ¥1,209,559,169.78, compared to ¥1,181,785,162.62 at the end of Q1 2021[20] - Total liabilities decreased to ¥79,599,509.84 in Q1 2022 from ¥87,043,804.13 in Q1 2021, a reduction of 8.3%[20] - The total current assets as of March 31, 2022, were CNY 634,640,443.66, a decrease of 4.3% from CNY 661,892,651.67 at the end of 2021[26] - The total liabilities decreased to CNY 78,400,640.36 as of March 31, 2022, down from CNY 118,663,389.52 at the end of 2021, representing a reduction of 33.9%[26] - The company’s total equity increased to CNY 870,997,432.68 as of March 31, 2022, up from CNY 831,443,152.87 at the end of 2021, reflecting a growth of 4.8%[26] Other Information - The company has not reported any significant new strategies or product developments during the quarter[17] - There are no significant changes in the top ten shareholders' participation in margin trading or securities lending[16] - The company has not provided any future performance guidance or outlook in the current report[17] - The financial statements for the quarter are unaudited[17] - The company plans to continue investing in new technologies and market expansion strategies to drive future growth[32]

Financial Performance - The company's operating revenue for Q3 2021 was ¥82,493,459.54, representing a year-on-year increase of 29.50%[5] - The net profit attributable to shareholders for the same period was ¥32,903,988.81, up 30.24% year-on-year[5] - The net profit excluding non-recurring gains and losses increased by 52.63% year-on-year, totaling ¥28,724,470.68[5] - Total revenue for the first three quarters of 2021 reached CNY 218,065,828.82, an increase of 9.6% compared to CNY 198,875,360.94 in the same period of 2020[23] - The net profit for Q3 2021 was CNY 91,141,021.54, an increase of 21% compared to CNY 75,321,723.83 in Q3 2020[24] - The total revenue for the first three quarters of 2021 reached CNY 253,434,207.87, up from CNY 203,925,255.68 in the same period of 2020, representing a growth of approximately 24%[26] - The operating profit for Q3 2021 was CNY 104,079,359.60, compared to CNY 87,742,498.89 in Q3 2020, indicating a year-over-year increase of about 18.5%[24] - The total comprehensive income for Q3 2021 was CNY 89,343,784.10, up from CNY 74,051,083.33 in Q3 2020, reflecting a growth of approximately 20.5%[25] Assets and Liabilities - The total assets at the end of the reporting period reached ¥1,142,260,254.76, a year-on-year increase of 173.72%[6] - The net assets attributable to shareholders increased by 237.38% year-on-year, totaling ¥1,064,024,194.07[6] - The total liabilities decreased to CNY 74,499,305.89 from CNY 97,618,152.50, a reduction of 23.7%[21] - Cash and cash equivalents rose significantly to CNY 261,456,378.44 from CNY 82,813,499.67, an increase of 215.5%[20] Research and Development - Research and development expenses amounted to ¥10,221,356.39, a 51.45% increase compared to the same period last year, accounting for 12.39% of operating revenue[6] - Research and development expenses increased to CNY 26,690,385.58 in 2021 from CNY 18,879,475.54 in 2020, marking an increase of 41.5%[23] - The company has developed several new products, including a 4K ultra-high-definition imaging system and an automatic defogging endoscope system, which are currently undergoing technical reviews and registration[18] - The company is preparing for mass production of multiple models of non-contact palm vein modules and terminals, achieving a false rejection rate (FRR) of less than 0.01% and a false acceptance rate (FAR) of 0.00001%[18] - The company has submitted production license applications for its 1080P HD camera system and is in the process of technical evaluation for its 4K ultra HD camera system[18] Cash Flow and Investments - Cash flow from operating activities increased by 12.90% year-on-year, primarily due to increased sales collections and government subsidies[7] - Cash paid for purchasing goods and services increased to 47.51 million, reflecting higher expenditures during the reporting period[12] - Tax payments amounted to 47.74 million, showing a year-on-year increase in value-added tax, corporate income tax, and customs duties[12] - Cash paid for the construction of fixed assets rose to 86.87 million, indicating increased investment in the second-phase factory construction[12] - Investment cash outflows increased significantly to 95,206.12 million, primarily due to higher spending on financial products during the reporting period[12] - The total cash outflow from investment activities in Q3 2021 was CNY 528,860,990.87, compared to CNY 54,308,785.80 in Q3 2020, indicating a substantial increase in investment expenditures[27] Market and Future Plans - The revenue from medical endoscope products accounted for 77.19% of total revenue in Q3, with a year-on-year increase of 56.16%[7] - The company received government subsidies totaling ¥910,248.05 during the reporting period, contributing to the net profit increase[10] - The company plans to continue expanding its market presence and investing in R&D to enhance product offerings and meet customer demand[7] - The company has no new bank borrowings during the reporting period, indicating a stable financing strategy[12] - There were no cash outflows related to the acquisition of subsidiaries during the reporting period, reflecting a pause in M&A activities[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 2,800, with the top ten shareholders holding a combined 12.55% of shares[14] - The company distributed dividends totaling 34.79 million to shareholders, with additional interest payments of 2,405.47 million for bank loans[12] Tax and Refunds - The company received CNY 14,782,531.44 in tax refunds during the first three quarters of 2021, compared to CNY 3,812,030.54 in the same period of 2020[26]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of 500 million RMB, representing a growth of 25% compared to the same period last year[14]. - The company has set a revenue guidance for the second half of 2021, projecting an increase of 20% year-over-year, aiming for approximately 600 million RMB[14]. - The company's operating income for the first half of 2021 was approximately ¥135.57 million, a slight increase of 0.30% compared to the same period last year[22]. - Net profit attributable to shareholders increased by 17.28% year-on-year, reaching approximately ¥58.81 million, primarily due to increased government subsidies and investment income[22]. - The company achieved a revenue of 16,500,000.00 for its 4K ultra-high-definition imaging systems, with a gross profit of 10,060,649.23, indicating a strong performance in the medical imaging sector[84]. - The company reported a total revenue from sales and services of CNY 43,420,603.92 for the first half of 2021, compared to CNY 38,063,835.52 in the same period of 2020, reflecting an increase of approximately 14.5%[185]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting international markets with a focus on Europe and North America, aiming for a 10% increase in overseas sales[14]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share within the next two years[140]. - The company aims to promote its own brand products in the domestic market to respond to national policies and drive the import substitution of high-end medical devices[104]. - The company is building a marketing network in Shandong province and has established clinical cooperation centers with multiple hospitals to enhance market penetration[100]. Research and Development - The company has completed a strategic acquisition of a technology firm, which is anticipated to enhance its R&D capabilities and product offerings[14]. - Research and development expenses accounted for 12.15% of operating income, an increase of 3.17 percentage points year-on-year, reflecting new product development efforts[21]. - The company has developed a complete solution for optical technology and minimally invasive applications, integrating design, manufacturing, and quality inspection capabilities[91]. - The company has established a clear R&D system with multiple research departments focusing on cutting-edge technologies and clinical applications, ensuring coordinated technology and product planning[41]. - The company is focusing on enhancing its technological capabilities and exploring potential mergers and acquisitions to strengthen its market position[197]. Product Development and Innovation - New product development includes the launch of a next-generation imaging device, expected to enhance diagnostic capabilities and capture a larger market share[14]. - The company is actively developing 4K ultra-high-definition imaging technology and multi-spectral integrated light source technology, with the 4K ultra-high-definition camera system set to submit a registration application soon[34]. - The company is developing new products including endoscope light sources and imaging systems, which are expected to enhance the sales scale of its proprietary brand[50]. - The company is currently developing a high-temperature steam sterilization compatible imaging system, which is expected to reduce cross-contamination risks significantly[84]. Financial Position and Cash Flow - The company has maintained a strong cash position, with cash reserves amounting to 200 million RMB, providing flexibility for future investments[14]. - The net cash flow from operating activities increased by 49.12% to approximately ¥63.41 million, mainly due to higher government subsidies received during the reporting period[23]. - The total assets grew by 166.27% year-on-year, reaching approximately ¥1.11 billion, largely due to increased capital and cash reserves following the company's IPO[22]. - The company reported a significant increase in cash and cash equivalents, reaching CNY 276.75 million, a 234.18% increase from CNY 82.81 million last year[111]. Risk Management - The management has identified potential risks related to supply chain disruptions, which could impact production timelines and costs[4]. - The company is closely monitoring foreign exchange fluctuations and will utilize hedging tools to mitigate risks associated with currency volatility[105]. Shareholder and Corporate Governance - The board has confirmed that there are no significant non-operational fund usages by controlling shareholders or related parties during the reporting period[7]. - The company has committed to a 36-month lock-up period for major shareholders following the IPO, with specific conditions for share transfers[131]. - The company has established a clear framework for managing share transfers to ensure compliance and protect shareholder interests[135]. Environmental and Social Responsibility - The company strictly complies with environmental protection laws and regulations, with no penalties for violations reported during the reporting period[128]. - Wastewater is mainly generated from domestic sewage and optical processing, with treatment measures including sedimentation before connecting to municipal sewage systems[124]. - The company has implemented measures to control dust and non-methane total hydrocarbons emissions from glass cutting and processing, including the use of cooling liquids and activated carbon adsorption[125].

Financial Performance - Net profit attributable to shareholders decreased by 13.78% to CNY 24,968,512.42 compared to the same period last year[5]. - Operating revenue decreased by 6.16% to CNY 67,158,223.15 compared to the previous year[5]. - Basic and diluted earnings per share decreased by 23.40% to CNY 0.36[5]. - The company reported a net profit of ¥29,505,206.13 for Q1 2021, compared to ¥35,711,202.33 in Q1 2020, reflecting a decline of 17.3%[29]. - The company reported a total comprehensive income of CNY 554,326.46 for Q1 2021, a decrease from CNY 106,418,992.81 in Q1 2020[34]. - The company experienced a revenue impact of over CNY 4 million due to exchange rate fluctuations[7]. Assets and Liabilities - Total assets increased by 174.65% to CNY 1,146,144,171.35 compared to the end of the previous year[5]. - The company's total assets amounted to ¥1,146,144,171.35, compared to ¥417,311,065.60 at the end of 2020, showing a growth of approximately 174%[22]. - The total current assets reached ¥910,394,895.61, up from ¥194,341,487.84 in the previous year, indicating a substantial increase in liquidity[21]. - The total liabilities decreased slightly to ¥104,843,552.22 from ¥97,618,152.50, indicating a stable financial position despite the increase in assets[23]. - The company's total liabilities decreased to ¥77,401,444.52 from ¥97,962,204.57, indicating improved financial health[27]. Cash Flow - Cash flow from operating activities increased by 24.62% to CNY 31,378,337.96 compared to the same period last year[5]. - The net cash flow from operating activities for Q1 2021 was ¥31,378,337.96, an increase of 24.8% compared to ¥25,178,214.84 in Q1 2020[37]. - Total cash inflow from operating activities reached ¥63,837,158.07, up 160.0% from ¥24,537,667.75 in the same period last year[38]. - The cash inflow from operating activities was primarily driven by sales of goods and services, which generated ¥23,360,622.81, up from ¥16,211,302.85 in Q1 2020[38]. - Cash and cash equivalents increased to ¥595,202,677.31 from ¥19,521,474.02, showing a significant growth in liquidity[26]. - The company's cash and cash equivalents increased to ¥795,720,865.79 as of March 31, 2021, compared to ¥82,813,499.67 at the end of 2020, reflecting a significant growth[21]. Research and Development - R&D expenses accounted for 10.90% of operating revenue, an increase of 4.31 percentage points[6]. - Research and development expenses surged by 55.27% to ¥7,322,569.49, influenced by increased salary standards and external research costs[16]. - Research and development expenses increased to ¥7,322,569.49 in Q1 2021, up from ¥4,716,174.18 in Q1 2020, highlighting a focus on innovation[29]. - Research and development expenses for Q1 2021 were CNY 3,824,385.44, up from CNY 2,156,737.41 in Q1 2020, representing an increase of approximately 77.5%[33]. Shareholder Information - The total number of shareholders reached 5,431 by the end of the reporting period[12]. - The owner's equity rose significantly to ¥1,041,300,619.13 from ¥319,692,913.10, reflecting a growth of about 226%[23]. - Shareholders' equity rose to ¥918,147,368.37 from ¥222,142,363.90, demonstrating strong growth in owner’s equity[27]. Expenses and Costs - Increased management and R&D expenses were attributed to higher listing-related costs and salary adjustments[7]. - The company’s management expenses increased by 40.00% to ¥8,286,426.01, reflecting higher costs associated with the listing and salary adjustments[16]. - Total operating costs for Q1 2021 were ¥38,718,559.75, an increase of 6.3% from ¥36,437,730.11 in Q1 2020[29]. - The company paid ¥23,660,736.27 in employee-related cash payments, up from ¥19,026,751.07 in the previous year[37]. Government Support - The company reported a substantial increase in government subsidies received, totaling ¥22,807,771.25 in the first quarter, compared to ¥1,818,322.03 in the same period last year, marking an increase of approximately 1154.33%[17]. - The company received government industry development special funds, resulting in deferred income of ¥11,400,000.00[16].

Financial Performance - The company's operating revenue for 2020 was CNY 275,197,324.95, representing an increase of 8.83% compared to CNY 252,866,320.49 in 2019[22]. - The net profit attributable to shareholders for 2020 was CNY 96,351,767.88, a year-on-year increase of 33.95% from CNY 71,930,843.26 in 2019[22]. - The net cash flow from operating activities increased by 37.39% to CNY 114,777,995.62 in 2020, up from CNY 83,539,980.05 in 2019[25]. - The basic earnings per share for 2020 was CNY 1.48, a growth of 37.04% compared to CNY 1.08 in 2019[23]. - The company's total assets as of the end of 2020 were CNY 417,311,065.60, reflecting a 26.53% increase from CNY 329,819,312.40 at the end of 2019[22]. - The company's net assets attributable to shareholders increased by 43.26% to CNY 315,379,210.47 at the end of 2020, compared to CNY 220,142,950.95 at the end of 2019[22]. - The company achieved total revenue of 111.8 million with a net profit of 30.92 million, reflecting a profit margin of approximately 27.7%[109]. - The revenue from medical endoscope devices was 202.29 million yuan, showing a growth of 9.33% year-on-year, and accounted for 73.69% of the main business revenue[123]. Dividend Policy - The company plans to distribute a cash dividend of RMB 4.00 per 10 shares, totaling RMB 34,792,000.00, which accounts for 36.11% of the net profit attributable to shareholders for the year 2020[6]. - The company has established a cash dividend policy that prioritizes cash distributions when conditions allow, ensuring at least 10% of the distributable profit is allocated for cash dividends annually[184]. - No stock dividends or capital reserve transfers are planned for the year 2020, maintaining a clear focus on cash dividends[185]. - The cash dividend distribution plan is subject to approval at the upcoming shareholders' meeting, with adjustments to be made if the total share capital changes before the record date[185]. - The company has maintained a consistent dividend distribution strategy over the past three years, with a notable increase in cash dividends in 2018 and 2020[186]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The board of directors and supervisory board members have all attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has confirmed that there are no instances of more than half of the directors being unable to guarantee the authenticity of the annual report[9]. - The company has adhered to its profit distribution principles and policies, ensuring compliance and transparency in decision-making processes[186]. - The company is committed to maintaining transparency and compliance with the Shanghai Stock Exchange's disclosure obligations[190]. Research and Development - The total R&D investment for the year was approximately ¥30.92 million, representing an 8.35% increase from the previous year, with R&D expenses accounting for 11.24% of operating revenue[105]. - The company has established a structured R&D system that includes a central R&D department and various specialized research divisions, ensuring coordinated technology and product planning[40]. - The company emphasizes a layered project mechanism for R&D, with "conversion generation" products including 4K ultra HD fluorescence/white light laparoscopes[41]. - The company has developed high-performance medical devices, including HD fluorescence laparoscopes and HD white light laparoscopes, which are in the product registration phase[35]. - The company is actively researching and developing high-resolution confocal fluorescence endoscopes for early lung cancer detection, combining confocal microscopy technology with endoscopy[64]. Market and Sales Strategy - The company is actively expanding its domestic market while maintaining its international business scale, aiming to create new growth points[38]. - The company is enhancing its marketing network and clinical collaboration platforms to expand its self-branded products in major domestic markets[49]. - The company plans to enhance its marketing network to improve domestic market share, which is currently dominated by imported brands[128]. - The company is expanding its market presence with new product offerings and technological advancements in the medical imaging sector[110]. Risks and Challenges - The company reported no significant risks that could materially affect its operations during the reporting period[4]. - The company has outlined potential risks related to forward-looking statements in the report[7]. - The company relies heavily on sales to Stryker, which poses a risk to revenue stability if Stryker's business deteriorates[127]. - Financial expenses increased significantly due to higher bank borrowings and foreign exchange losses, totaling CNY 5.03 million in 2020[137]. Product Development and Innovation - The company has established four core technology platforms: optical technology, precision machinery technology, electronic technology, and digital image technology, enhancing its competitive edge in the medical imaging field[66]. - The company is actively developing 4K ultra-high-definition imaging technology and light source technology to enhance its product offerings in the endoscope market[57]. - The company has successfully developed a 4K ultra-high-definition laparoscope and 4K ultra-high-definition camera system, which are currently in the registration process, preparing for market expansion[62]. - The company is focusing on the development of composite endoscope products that combine various imaging technologies to meet the increasing demand for detailed surgical visualization[63]. - The company has developed a high-definition fluorescence laparoscope with 1080P full HD resolution, distortion less than 10%, and numerical aperture approximately 20% higher than conventional laparoscopes[68].